Regulatory Information
BEACONS PHARMACEUTICALS PTE. LTD.
BEACONS PHARMACEUTICALS PTE. LTD.
Therapeutic
Pharmacy Only
Formulation Information
TABLET, FILM COATED
**DOSAGE:** Suppression in adults: 500mg (300mg base) on the same day each week, beginning 2 weeks prior to exposure, continued for 4 – 8 weeks after leaving the area. If treatment begins on exposure, a loading dose of 1 gm can be taken in divided doses 6 hours apart. Suppression in children: 5mg base/kg/week. The loading dose is 10mg base/kg/week. Acute attacks in adults: an initial dose of 1 gm (600mg base), followed by 500mg (300mg base) after 6 to 8 hours and a single dose of 500mg (300mg base) on each of 2 consecutive days. For children: A total of 25mg / kg is given over 3 days.First dose: 10mg base/kgSecond dose: 5mg base/kg, 6 hours after the first doseThird dose: 5mg base/kg, 18 hours after the second doseFourth Dose: 5mg base/kg, 24 hours after the third dose For a radical cure of vivax and malariae malaria, concomitant therapy with an 8-aminoquinoline compound like primaquine is necessary.
ORAL
Medical Information
**THERAPEUTIC PROPERTIES:** Chloroquine is used for the suppression and treatment of malaria. It is especially active against the erythrocytic forms of malaria parasites. It is not active against tissue forms of the malaria parasites.
**CONTRAINDICATIONS:** Chloroquine is contraindicated in the presence of retinal or visual field changes of any aetiology, in patients with psoriasis or porphyria, and in patients with known hypersensitivity to 4-aminoquinolines. However, the drug can be used in these cases in acute attacks of malaria if the physician elects to use it after carefully weighing the possible risks and benefits to the patient.
P01BA01
chloroquine
Manufacturer Information
BEACONS PHARMACEUTICALS PTE. LTD.
BEACONS PHARMACEUTICALS PTE. LTD.
Active Ingredients
Documents
Package Inserts
Chloroquine PI (proposed).pdf
Approved: May 26, 2022